

LAW OFFICES
GOLDBERG, GODLES, WIENER & WRIGHT
1229 NINETEENTH STREET, N.W.
WASHINGTON, D.C. 20036-2413

HENRY GOLDBERG
JOSEPH A. GODLES
JONATHAN L. WIENER
LAURA A. STEFANI
DEVENDRA ("DAVE") KUMAR

(202) 429-4900
TELECOPIER:
(202) 429-4912

e-mail:
general@g2w2.com
website: www.g2w2.com

HENRIETTA WRIGHT
THOMAS G. GHERARDI, P.C.
COUNSEL

THOMAS S. TYCZ*
SENIOR POLICY ADVISOR
*NOT AN ATTORNEY

December 15, 2005

Electronic Filing

Ms. Marlene H. Dortch
Federal Communications Commission
445 12th Street, SW
Washington, DC 20554

Re: ET Docket No. 05-213
Notification of Ex Parte Presentation


Dear Ms. Dortch:

On December 14, 2005, with regard to the above-referenced proceeding, the attached email was sent to Fred Campbell, Legal Advisor to Chairman Martin.

The email expresses the urgent need by the medical community for the Commission to take prompt, favorable action and grant DexCom its requested waiver so that its technology may be made available to diabetics.

Please direct questions concerning this matter to the undersigned.

Sincerely,


Laura Stefani
Attorney for DexCom, Inc.

cc: Fred Campbell

From: Steve Edelman [mailto:svedelman@vapop.ucsd.edu]
Sent: Wednesday, December 14, 2005 9:43 PM
To: Fred.Campbell@fcc.gov
Subject: Continuous Glucose Monitoring and Diabetes

Dear Fred,

I am writing to you as an endocrinologist specializing in diabetes and as a person living with type 1 diabetes since 1970. I am certainly not an expert on RF rules and regulations but I can tell you this technology is urgently needed by millions of people living with diabetes and especially those with insulin requiring diabetes.

As the medical community tries to get the glucose levels under tight control in patients to avoid the eye, kidney, nerve and heart disease associated with poor control, the risk of severe hypoglycemia goes up dramatically and often leads to car accidents, work related injuries, brain damage and not uncommonly death.

Continuous glucose monitoring has been "on the horizon" for too long with many companies trying hard but not coming close such as Cygnus, the makers of the GlucoWatch. As you know there are several companies currently working on a CGM device and I would encourage you to allow this technology to get to the market as soon as possible as long as they meet your accuracy standards and not be distracted by clinically unrelated issues. It is obviously a competitive market and sometimes the health and well fare of the patients are put lower on the priority list.

Please do not hesitate to call me for any questions or concerns. I would be happy to speak to you or someone from your staff at any time. (cell is 619 339 3112).

Sincerely,

Steve

Steven Edelman MD
Professor of Medicine
University of California San Diego
Veterans Affairs Medical Center

3350 La Jolla Village Drive (111G)
San Diego California 92161
Direct Line: 858 552 8585 x 7361
Fax: 858 642 6242
Pager: 858 347 1630

Founder and Director
Taking Control of Your Diabetes 501(c)3
1110 Camino Del Mar
Suite B
Del Mar, California 92014
Office: 858 755 5683
Fax: 858 755 6854

<http://www.tcloyd.org>